Instant coffee may damage your eyes, genetic study finds

	Ophthalmology & Optometry
	The latest ophthalmology / optometry news from News Medical

	Instant coffee may damage your eyes, genetic study finds Researchers used genomic and Mendelian randomization analyses in over 500,000 individuals to reveal a statistically significant causal link between instant coffee intake and increased risk of dry age-related macular degeneration (AMD). No such risk was found for ground or decaffeinated coffee.

	Artificial intelligence advances early detection and management of myopia The increasing prevalence of myopia is a global health concern, with high myopia increasing the risk of vision damage.

			New app helps relieve dry eye through optimized blinking routine An Aston University optometrist, Professor James Wolffsohn, has determined an optimum blinking exercise routine for people suffering with dry eye disease, and has developed a new app, MyDryEye, to help them complete the routine to ease their symptoms.

			Study identifies potential way to slow or block progression of age-related macular degeneration A new study from Washington University School of Medicine in St. Louis identifies a possible way to slow or block progression of age-related macular degeneration, a leading cause of blindness in people over age 50.

			Targeting ADAM10 may offer hope for retinal disease treatment New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) regulates abnormal blood vessel growth in the damaged retina, which can cause vision loss or impairment.

	First patient treated in international clinical trial for rare muscle-weakness disease The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease known as Myasthenia Gravis.

	Cas13d gene editing shows promise for glaucoma treatment Gene editing with CRISPR shows promise in treating glaucoma by reducing intraocular pressure without permanent DNA changes, paving the way for future therapies.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2025